Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (22505)	6/18/1998 11:25:00 PM
From: Henry Niman	Respond to of 32384

Bernie, It's my understanding that these are proprietary compounds that are well covered by LGND patents which is one of the reasons that LGND has 75 scientists working in this area. The first IND is expected to be filed this year and the lead candidate, LGD1331, should enter the clinic early next year. I'm not sure if LGND is going to run with this on their own, or license out some of the non-cancer applications (BPH, male pattern baldness), but it's my understanding that they will run with the initial clinicals, which will create more value for any subsequent deals.